Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:47:19.904Z.
Calculation as of: 2026-10-06T14:47:19.904Z.
Quote observation: 2026-10-06T14:45:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3ba604bfa669edc564cc368ab96d70220aa63ab01e3d3e65254ff63c7dd77471
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$145.59M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.58M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.71M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$139.33M
EV/EBITDA Ratio
449.35x
TTM Avg
352.35x
3Y Avg
117.66x
5Y Avg
91.76x
Market Cap
$147.97M
EV/EBITDA Ratio
N/A
TTM Avg
159.13x
3Y Avg
159.13x
5Y Avg
159.13x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immuneering Corporation (IMRX) | $143.76M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $145.59M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.58M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $140.10M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $146.71M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $139.33M | 449.35x | 352.35x | 117.66x | 91.76x |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | N/A | 159.13x | 159.13x | 159.13x |
| Alpha Cognition Inc (ACOG)vs › | $138.69M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $137.77M | N/A | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $136.65M | N/A | 693.21x | 347.06x | 258.50x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
